Improving glioblastoma treatment by targeting tumor blood vessels and immune cells
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2
This study is looking at ways to make immunotherapy work better for people with glioblastoma by changing the environment around the tumor, so that immune cells can reach it more easily and fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11042169 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor, and aims to enhance the effectiveness of immunotherapy by modifying the tumor microenvironment. The approach involves co-targeting two key factors, VEGF and Ang2, which are involved in the abnormal blood vessel formation within the tumor. By addressing these factors, the research seeks to improve the delivery of immune cells to the tumor and reduce the immunosuppressive environment that hinders treatment. Patients may benefit from a more effective immunotherapy regimen that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded adequately to standard treatments.
Not a fit: Patients with non-glioblastoma brain tumors or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment responses for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in modifying the tumor microenvironment to enhance immunotherapy, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Fukumura, Dai — Massachusetts General Hospital
- Study coordinator: Fukumura, Dai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.